Abstract: Disclosed herein are efflux pump inhibitors and pharmaceutical compositions comprising the same. The efflux pump inhibitors may be used in methods of preventing antibiotic resistance in a subject, and in methods of treating a bacterial infection in a subject. The efflux pump inhibitor may be co-administered with an antibiotic.

Abstract: The present invention relates to iron complex compounds for therapeutic use which are low in arsenic, chromium, lead, cadmium, mercury and/or aluminum, compositions thereof and processes for preparing said iron complex compounds.

Abstract: The present invention disclosed an improved one pot, one step process for halogenation of compound of formula (II) to afford corresponding halogenated compound of formula (I) having improved yield and increased selectivity under very mild conditions.

Abstract: There is disclosed an electroactive composition including (a) a host compound having Formula I and (b) a photoactive dopant. In Formula I: R1 is the same or different at each occurrence and is D, alkyl, silyl, germyl, deuterated alkyl, deuterated silyl, or deuterated germyl; a is an integer from 0-7; b is an integer from 0-8; c is an integer from 0-4; and d is an integer from 0-7.

Abstract: Provided is a method for preparing a diol. In the method, a saccharide and hydrogen as raw materials are contacted with a catalyst in water to prepare the diol. The employed catalyst is a composite catalyst comprised of a main catalyst and a cocatalyst, wherein the main catalyst is a water-insoluble acid-resistant alloy; and the cocatalyst is a soluble tungstate and/or soluble tungsten compound. The method uses an acid-resistant, inexpensive and stable alloy needless of a support as a main catalyst, and can guarantee a high yield of the diol in the case where the production cost is relatively low.

Abstract: The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KED) biocatalyst enzymes and methods of using the biocatalysts.

Abstract: The present invention relates to a chemical deposition raw material for manufacturing an iridium thin film or an iridium compound thin film by a chemical deposition method, including an iridium complex in which cyclopropenyl or a derivative thereof and a carbonyl ligand are coordinated to iridium. The iridium complex that is applied in the present invention enables an iridium thin film to be manufactured even when a reducing gas such as hydrogen is applied. in which R1 to R3, which are substituents of the cyclopropenyl ligand, are each independently hydrogen, or a linear or branched alkyl group with a carbon number of 1 or more and 4 or less.

Abstract: The invention relates to a method of producing compound (I) by (A) reacting compound (II) formaldehyde and hydrogen in the presence of a metal catalyst, in a solvent, wherein the amount of the formaldehyde to be used is exceeding 1 mol and not exceeding 5 mol per 1 mol of compound (II), to obtain a mixture containing the formaldehyde and compound (I), and (B) mixing the obtained mixture containing the formaldehyde and compound (I) with hydrogen and a secondary amine selected from the group consisting of diethylamine, dipropylamine, diisopropylamine, butylethylamine, pyrrolidine, piperidine and morpholine, in the presence of a metal catalyst, in a solvent, and then removing the metal catalyst, followed by obtaining the compound (I) by distillation.

Abstract: [OBJECT] To provide a metal-organic framework having high hygroscopicity under low humidity conditions, and a method for producing such a metal-organic framework. [SOLVING MEANS] A method for producing a coordinatively unsaturated metal-organic framework includes the steps of providing a precursor metal-organic framework comprising a metal cluster and a polycarboxylic acid ion and a monocarboxylic acid ion coordinated to the metal cluster, and allowing the precursor metal-organic framework and a metal salt having a Lewis acidity to coexist in a solvent to desorb at least a part of the monocarboxylic acid ion, which is coordinated to the metal cluster, from the metal cluster, as well as a coordinatively unsaturated metal-organic framework, including an M6O8-x(OH)x-type metal cluster and carboxylic acid ions including a polycarboxylic acid ion as a polydentate ligand and a C1-3 monocarboxylic acid ion as a monodentate ligand coordinated to the metal cluster.

Abstract: A complex has a structure of formula (1A): SnXn·(m)L, wherein X is at least one type of halogen atoms, L is a polar solvent molecule, n is a value from 1.5 to 2.5, and m is a value from 0.3 to 1.9. A perovskite compound has a structure of formula (2A): RSnXj, wherein Sn has an oxidation number from 1.5 to 2.5, R is at least one type of a monovalent cation, X is at least one type of halogen atoms, and j is a value from 2.5 to 3.5, and the perovskite compound is free of tin oxide; or a perovskite compound has a structure of formula (2B): R2M2BiX1, wherein R is at least one type of a monovalent cation, X is at least one type of halogen atoms; M2 is a monovalent metal, and i is a value from 5.0 to 7.0.

Abstract: A process is disclosed for making CF3CF?CHF. The process involves reacting CF3CClFCCl2F with H2 in a reaction zone in the presence of a catalyst to produce a product mixture comprising CF3CF?CHF. The catalyst has a catalytically effective amount of palladium supported on a support selected from the group consisting of alumina, fluorided alumina, aluminum fluoride and mixtures thereof and the mole ratio of H2 to CF3CClFCCl2F fed to the reaction zone is between about 1:1 and about 5:1. Also disclosed are azeotropic compositions of CF3CClFCCl2F and HF and azeotropic composition of CF3CHFCH2F and HF.

Abstract: Disclosed herein is the use of manganese, iron, cobalt, or nickel complexes containing tridentate pyridine di-imine ligands as hydrosilylation catalysts. These complexes are effective for efficiently catalyzing hydrosilylation reactions, as well as offering improved selectivity and yield over existing catalyst systems.

Abstract: A trichlorogermanide of formula (I): [R4N]/[R4P]Cl[GeCl3] (I), where R is Me, Et, iPr, nBu, or Ph, tris(trichlorosilyl)germanide of formula (II): [R4N]/[RrP][Ge(SiCl3)3] (II), where R is Me, Et, iPr, nBu, or Ph, a tris(trichlorosilyl)germanide adduct of GaCl3 of formula (III): [Ph4P][Ge(SiCl3)3*GaCl3], and a tris(trichlorosilyl)germanide adduct of BBr3 of formula (IV): [Ph4P][Ge(SiCl3)3*BBr3]. Also, methods for preparing the trichlorogermanides of formula (I), the tris(trichlorosilyl)germanide of formula (II), the tris(trichlorosilyl)germanide adduct of BBr3 of formula (IV).

Abstract: Provided herein is a multifunctional particle and methods of forming the same. The multifunctional particle includes a surface of the particle; a first moiety coupled to the surface and having at least one substantially hydrophobic appendage; and a second moiety coupled to the surface and having at least one appendage comprising a reactive functional group and a substantially hydrophilic repeating unit, whereby the particle is substantially superhydrophobic as a result of the substantially hydrophobic appendage, chemically reactive as a result of the reactive functional group, and migratory to a surface of a substantially hydrophobic matrix in which the particle may be included as a result of the substantially hydrophilic repeating unit. Additionally, antimicrobial functional groups may be coupled to the surface.

Abstract: The present invention provides processes for the preparation of zuclomiphene, as well as intermediates useful in the preparation thereof. In particular, processes are provided for the carbometallation of diphenylacetylene with a compound of Formula (3) to afford either zuclomiphene or an intermediate which is converted to zuclomiphene.

Abstract: The present invention provided a continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts. Diazotization, reduction, acidic hydrolysis and salifying with acids are innovatively integrated together. Using acidic liquids of aniline or substituted aniline, diazotization reagents, reductants and acids as raw materials, phenylhydrazine derivative salts is obtained through the synthesis process, which is a three-step continuous tandem reaction including diazotization, reduction, acidic hydrolysis and salifying. The described synthesis process is a kind of integrated solutions, which is carried out in an integrated reactor. The feed inlets of the integrated reactor are continuously filled with raw materials. In the integrated reactor, diazotization, reduction, acidic hydrolysis and salifying are carried out continuously and orderly, and phenylhydrazine salts or substituted phenylhydrazine salts is obtained in the outlet of the integrated reactor without interruption.

Abstract: This method is for producing a transition metal complex represented by formula (2), the method comprising reacting a compound containing a transition metal selected from V, Cr, Mo, W, Fe, Ru, Co, Rh, Ni, Pd, and Pt with an isocyanide compound represented by formula (1) in the presence of an alkali metal supported by a solid substance which is insoluble in an organic solvent. This production method can be used to easily and efficiently produce a transition metal complex that includes a predetermined transition metal having an oxidation number of 0 and that has the same or different isocyanide compounds, without using a compound harmful to the human body. (1): (CN)x—R1 {R1 represents a mono- to tri-valent organic group having 1-30 carbon atoms, and x represents an integer of 1-3}.

Abstract: An object of the present invention is to provide a novel complex having at least one carbon-carbon double bond and/or carbon-carbon triple bond, and having at least one Diels-Alder reactive functional group such as tetrazine. The present invention provides a complex represented by a formula (1): [M4O(RCOO)6]p??(1) wherein in the formula (1), at least one of R is an alkenyl group having 2 to 18 carbon atoms or an alkynyl group having 2 to 18 carbon atoms, and at least one of R is a monovalent group represented by a structural formula (2), wherein in the structural formula (2), A1 to A4 each independently represent a nitrogen atom or a carbon atom, X1 represents a single bond or a divalent organic group, and R1 represents a hydrogen atom or a monovalent organic group.

Abstract: A method for safely and efficiently producing high-purity dialkylaminosilane. Dialkylamine is fed simultaneously during feeding chlorosilane in the presence of metal to cause reaction. For example, chlorosilane and dialkylamine are fed, and then only dialkylamine is fed to cause reaction, whereby dialkylaminosilane is produced.

Abstract: The method relates to the field of asymmetric allylic amination and comprises preparing a chiral N-substituted allylic amine compound from the corresponding allylic substrates and substituted hydroxylamines, in the presence of a catalyst, said catalyst comprising copper compounds and a chiral ligand. Examples of chiral amine compounds which can be made using the method include Vigabatrin, Ezetimibe Terbinafine, Naftifine 3-methylmorphine, Sertraline, Cinacalcet, Mefloquine hydrochloride, and Rivastigmine. There are over 20,000 known bioactive molecules with chiral N-substituted allylic amine substructure. The method may also be used to produce non-natural chiral 13-aminoacid esters, a sub-class of chiral N-substituted allylic amine compounds. Examples of 13-aminoacid ester which can be produced by the disclosed method, include, but are not limited to, N-(2-methylpent-1-en-3-yl)benzenamine and Ethyl 2-methylene-3-(phenylamino)butanoate.